• Summit Therapeutics average return on tangible equity for 2024 was -121.13, a 77.27% decline from 2023.
• Summit Therapeutics average return on tangible equity for 2023 was -532.85, a 365.05% decline from 2022.
• Summit Therapeutics average return on tangible equity for 2022 was -114.58, a 9.8% increase from 2021.

Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.